person · Reporting owner

Fitzgerald Kevin Joseph

Disclosed activity across 2 companies

Tapewire entity: 53095
SEC CIK: 0001886431

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	CSO & EVP, Head of Research	March 04, 2026	March 06, 2026
Ovid Therapeutics Inc.OVID · Entity 5411	Director	April 07, 2026	April 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,569	Ending reported balance After 2026-03-05 transaction · row 12 12 source rows · reconciled sequence Row 1 · 2026-03-04 · Sale · Disposed 29 · Balance 21,831 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 28 · Balance 21,803 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 59 · Balance 21,744 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 79 · Balance 21,665 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 96 · Balance 21,569 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 210 · Balance 21,359 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 75 · Balance 21,284 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 57 · Balance 21,227 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 124 · Balance 21,103 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 233 · Balance 20,870 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 148 · Balance 20,722 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 153 · Balance 20,569 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Common StockSEC Table I · non-derivative	Indirectby Managed Account	537	Reported balance Holding disclosure · report date 2026-03-04 · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · Balance 537 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Ovid Therapeutics Inc.

Report date April 07, 2026 · Filed April 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,578	Reported balance After 2026-04-07 transaction · row 1 1 source row Row 1 · 2026-04-07 · Grant · Acquired 17,578 · Balance 17,578 F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 26, 2024 Filed Nov 27, 2024 22:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	215	$249.60	$53,664.00	Disclosure SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,640 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
November 26, 2024 Filed Nov 27, 2024 22:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	26	$247.77	$6,442.02	Disclosure SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,855 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
November 25, 2024 Filed Nov 27, 2024 22:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,881 F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	6,667	$0.00 Strike: $97.72	$0.00	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · derivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2025-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F9 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 7, 2015. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	14,058	$0.00 Strike: $85.00	$0.00	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · derivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,192 Underlying: Common Stock · 14,058 shares Expires 2029-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F8 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 28, 2023. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	135	$274.65	$37,077.75	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,881 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1,158	$273.73	$316,979.34	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,016 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $273.32 to $274.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	3,913	$272.43	$1,066,018.59	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,174 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $272.23 to $272.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	5,736	$271.32	$1,556,291.52	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,087 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $271.02 to $271.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	9,662	$270.17	$2,610,382.54	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,823 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $269.90 to $270.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1,421	$268.66	$381,765.86	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,485 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $268.53 to $269.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	14,058	$85.00	$1,194,930.00	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:12 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	6,667	$97.72	$651,499.24	Disclosure SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	125	$235.19	$29,398.75	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 13 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,181 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	138	$234.66	$32,383.08	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,306 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	86	$233.53	$20,083.58	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,444 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	161	$232.54	$37,438.94	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,530 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	74	$231.59	$17,137.66	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,691 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	227	$229.93	$52,194.11	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,765 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	198	$229.06	$45,353.88	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,992 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	96	$228.30	$21,916.80	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,190 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	26	$226.82	$5,897.32	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,286 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	13	$225.55	$2,932.15	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,312 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	9	$224.17	$2,017.53	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,325 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	45	$221.71	$9,976.95	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,334 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:26 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantCommon Stock	2,498	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000065 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,379 F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024. Read SEC document
February 22, 2024 Filed Feb 26, 2024 22:56 UTC	Ovid Therapeutics Inc. OVID · Entity 5411	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0001209191-24-003960 · doc4.xml · derivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-02-21 F1 · derivative.exercise_date: The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:51 UTC	Ovid Therapeutics Inc. OVID · Entity 5411	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-23-013215 · doc4.xml · derivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date. Read SEC document
February 03, 2022 Filed Feb 5, 2022 01:49 UTC	Ovid Therapeutics Inc. OVID · Entity 5411	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.72	$0.00	Disclosure SEC source: 0001209191-22-007327 · doc4.xml · derivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date. Read SEC document
October 06, 2021 Filed Oct 7, 2021 20:44 UTC	Ovid Therapeutics Inc. OVID · Entity 5411	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.44	$0.00	Disclosure SEC source: 0001209191-21-059940 · doc4.xml · derivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-10-05 F1 · derivative.exercise_date: The option shall vest as follows: 1/36th of the shares subject to the option shall vest every month after October 6, 2021 such that the option will have vested in full on October 6, 2024, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) on each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.